Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults
Description
CONCLUSION: An in-development PCV21 vaccine would likely be economically and clinically favorable compared to currently recommended pneumococcal vaccines in older adults. While PCV21 was more favorable in Black cohort analyses, results for both Black